Biogene Ltd company information, Employees & Contact Information

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Biogen

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Biogen

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Biogen

CoLab | Community Lab Biogen

Biogen to Realign Resources for Alzheimer's Disease Franchise Biogen

News Biogen

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Biogen

Biogen to Acquire Reata Pharmaceuticals Biogen

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA Biogen

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease Biogen

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary Biogen

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia Biogen

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases Biogen

Company Biogen

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results Biogen

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP Biogen

Spinal Muscular Atrophy (SMA) Biogen

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Biogen

Biogen Completes Acquisition of Human Immunology Biosciences Biogen

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies Biogen

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union Biogen

Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biogen

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease Biogen

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis Biogen

Environment Biogen

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP Biogen

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity Biogen

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. Biogen

2024 Corporate Responsibility Report Biogen

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease Biogen

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia Biogen

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease Biogen

Biogen Board Appoints Two New Independent Directors Biogen

Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program Biogen

Biogen International Headquarters Biogen

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Biogen

Biogen Completes Acquisition of Reata Pharmaceuticals Biogen

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. Biogen

Medical Professionals Biogen

Lupus Biogen

Science & Innovation Biogen

Statement: Biogen Receives Favorable Decision from European Patent Office on Patent Related to TECFIDERA® (dimethyl fumarate) Biogen

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab) Biogen

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS Biogen

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration Biogen

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy Biogen

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience Biogen

Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) Biogen

Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke Biogen

Biogen Announces Intent to Spin off Its Hemophilia Business Biogen

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia Biogen

Biogen Completes Separation of Global Hemophilia Business, Bioverativ Biogen